Association between Chemotherapy-Response Assays and Subsets of Tumor-Infiltrating Lymphocytes in Gastric Cancer: A Pilot Study.
10.5230/jgc.2015.15.4.223
- Author:
Jee Youn LEE
1
;
Taeil SON
;
Jae Ho CHEONG
;
Woo Jin HYUNG
;
Sung Hoon NOH
;
Choong Bai KIM
;
Chung Gyu PARK
;
Hyoung Il KIM
Author Information
1. Department of Surgery, Yonsei University Health System, Yonsei University College of Medicine, Seoul, Korea. cairus@yuhs.ac
- Publication Type:Original Article
- Keywords:
Adenosine triphosphate;
Chemotherapy response assay;
Lymphocytes, tumor-infiltrating;
Stomach neoplasms;
Drug screening assays, antitumor
- MeSH:
Adenosine;
Adenosine Triphosphate;
Antibodies;
Cell Death;
Cisplatin;
Doxorubicin;
Drug Screening Assays, Antitumor;
Drug Therapy;
Epirubicin;
Etoposide;
Fluorouracil;
Gastrectomy;
Granzymes;
Humans;
Lymphocytes, Tumor-Infiltrating*;
Methotrexate;
Mitomycin;
Paclitaxel;
Pilot Projects*;
Stomach Neoplasms*
- From:Journal of Gastric Cancer
2015;15(4):223-230
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The purpose of this pilot study was to evaluate the association between adenosine triphosphate-based chemotherapy response assays (ATP-CRAs) and subsets of tumor infiltrating lymphocytes (TILs) in gastric cancer. MATERIALS AND METHODS: In total, 15 gastric cancer tissue samples were obtained from gastrectomies performed between February 2007 and January 2011. Chemotherapy response assays were performed on tumor cells from these samples using 11 chemotherapeutic agents, including etoposide, doxorubicin, epirubicin, mitomycin, 5-fluorouracil (5-FU), oxaliplatin, irinotecan, docetaxel, paclitaxel, methotrexate, and cisplatin. TILs in the tissue samples were evaluated using antibodies specific for CD3, CD4, CD8, Foxp3, and Granzyme B. RESULTS: The highest cancer cell death rates were induced by etoposide (44.8%), 5-FU (43.1%), and mitomycin (39.9%). Samples from 10 patients who were treated with 5-FU were divided into 5-FU-sensitive and -insensitive groups according to median cell death rate. No difference was observed in survival between the two groups (P=0.216). Only two patients were treated with a chemotherapeutic agent determined by an ATP-CRA and there was no significant difference in overall survival compared with that of patients treated with their physician's choice of chemotherapeutic agent (P=0.105). However, a high number of CD3 TILs was a favorable prognostic factor (P=0.008). Pearson's correlation analyses showed no association between cancer cell death rates in response to chemotherapeutic agents and subsets of TILs. CONCLUSIONS: Cancer cell death rates in response to specific chemotherapeutic agents were not significantly associated with the distribution of TIL subsets.
